EPSTEIN BECKER GREEN

Bradley Merrill Thompson Quoted in "FDA Seeks Input on Software-As-A-Med Device Regulation"

FierceHealthcare

October 14, 2016 | Media Coverage

Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm's Washington, DC, office, was quoted in *FierceHealthcare,* in "FDA Seeks Input on Software-As-A-Med Device Regulation," by Susan D. Hall.

Following is an excerpt:

"This is really huge, much bigger than many people might appreciate," Bradley Merrill Thompson, an attorney with Epstein Becker & Green, said in email to FierceHealthIT.

It would apply to a huge number of mobile apps, as well as stand-alone programs for PCs used in healthcare, Thompson said. Since clinical evaluation is typically the most expensive part of product development for them, the requirements will have a significant impact on the cost and time to market involved in developing them.

People

Bradley Merrill Thompson
Member of the Firm
Regulatory Strategy, Product Development, and Product Approvals
Washington, DC
202-861-1817
bthompson@ebglaw.com

Focus Areas

Services

Digital Health

Regulatory Strategy, Product Development, and Product Approvals

Industries

Health Care Industry

Medical Devices

Technology